EdgeMarket › What Commodore Capital Lp reported owning
What Commodore Capital Lp reported owning
As filed on Form 13F for the quarter ending 2026-03-31, up to 45 days after that date. Long-only US-listed equity — shorts, bonds, cash and non-US listings are not on the form, so this is one leg of the book, not the book.
Reported value
1.7BPositions
36Quarter
2026-03-31Shown below
36largest by value
| holding | value | % of book | shares | price | 1y |
|---|---|---|---|---|---|
| RLAY Relay Therapeutics, Inc. | 169.2M | 9.8% | 17.0M | 19.44 | +471.8% |
| ALKS Alkermes plc. | 148.5M | 8.6% | 4.2M | 48.33 | +66.8% |
| ELVN Enliven Therapeutics, Inc. | 128.4M | 7.4% | 3.3M | 59.82 | +204.3% |
| COGT Cogent Biosciences, Inc. | 111.2M | 6.4% | 2.9M | 36.73 | +209.6% |
| SYRE Spyre Therapeutics, Inc. | 96.5M | 5.6% | 1.9M | 106.49 | +551.3% |
| TYRA Tyra Biosciences, Inc. | 94.8M | 5.5% | 2.5M | 26.05 | +154.4% |
| CLDX Celldex Therapeutics, Inc. | 85.5M | 4.9% | 2.7M | 40.38 | +93.3% |
| unmapped CUSIP 670703107 | 85.4M | 4.9% | 833.6K | — | — |
| AMLX Amylyx Pharmaceuticals, Inc. | 78.5M | 4.5% | 5.7M | 38.66 | +381.4% |
| KYMR Kymera Therapeutics, Inc. | 62.5M | 3.6% | 750.0K | 119.80 | +182.9% |
| ANRO Alto Neuroscience, Inc. | 61.2M | 3.5% | 2.7M | 34.28 | +899.4% |
| PHVS Pharvaris N.V. | 54.2M | 3.1% | 1.9M | 36.27 | +57.7% |
| ERAS Erasca, Inc. | 51.4M | 3.0% | 3.2M | 17.63 | +1107.5% |
| DMRA Damora Therapeutics, Inc. | 50.2M | 2.9% | 1.9M | 30.82 | +811.9% |
| XENE Xenon Pharmaceuticals Inc. | 48.0M | 2.8% | 825.0K | 60.77 | +61.5% |
| DFTX Definium Therapeutics, Inc. | 37.8M | 2.2% | 2.0M | 44.91 | +375.2% |
| LBRX LB PHARMACEUTICALS INC | 37.0M | 2.1% | 1.5M | 47.62 | — |
| EYPT EyePoint, Inc. | 36.4M | 2.1% | 2.8M | 5.32 | -53.8% |
| NRIX Nurix Therapeutics, Inc. | 35.3M | 2.0% | 2.3M | 26.72 | +180.4% |
| CRVS Corvus Pharmaceuticals, Inc. | 33.0M | 1.9% | 2.3M | 14.46 | +178.6% |
| ASMB ASSEMBLY BIOSCIENCES, INC. | 27.8M | 1.6% | 1.0M | 34.38 | +31.5% |
| CATX Perspective Therapeutics, Inc. | 26.4M | 1.5% | 6.3M | 3.30 | -2.4% |
| unmapped CUSIP 834203309 | 21.8M | 1.3% | 652.4K | — | — |
| OCUL OCULAR THERAPEUTIX, INC | 21.8M | 1.3% | 2.6M | 11.08 | -7.4% |
| IPSC Century Therapeutics, Inc. | 19.7M | 1.1% | 8.7M | 2.07 | +279.8% |
| ZURA Zura Bio Ltd | 19.3M | 1.1% | 3.2M | 5.85 | +234.3% |
| SABS SAB Biotherapeutics, Inc. | 16.9M | 1.0% | 4.4M | 3.78 | +88.1% |
| PALI PALISADE BIO, INC. | 12.6M | 0.7% | 7.2M | 2.10 | +191.7% |
| KPTI Karyopharm Therapeutics Inc. | 10.9M | 0.6% | 1.9M | 1.96 | -69.8% |
| IKT Inhibikase Therapeutics, Inc. | 9.1M | 0.5% | 5.4M | 2.39 | +42.3% |
| ANTX AN2 Therapeutics, Inc. | 8.0M | 0.5% | 2.3M | 5.81 | +418.8% |
| PEPG PepGen Inc. | 7.9M | 0.5% | 4.5M | 3.14 | +155.3% |
| AVTX Avalo Therapeutics, Inc. | 7.2M | 0.4% | 483.0K | 19.83 | +115.1% |
| HLXC Helix Acquisition Corp. III | 5.1M | 0.3% | 500.0K | 10.93 | — |
| LONA LeonaBio, Inc. | 4.8M | 0.3% | 464.4K | 7.68 | +92.8% |
| RLMD RELMADA THERAPEUTICS, INC. | 4.4M | 0.3% | 633.9K | 4.63 | +655.9% |
A position that grew quarter on quarter may simply reflect a higher price: if the stock rose 40% and the manager did nothing, the reported value rose 40%. Reading that as accumulation is reading the price back to yourself. More on that →
The whole archive is one click away.
Screener, filings, insider flow, backtests and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →